Furthermore, given the widespread expression of NKG2D ligands across various tumor types, the NKG2D/CD28 CCR exhibits broad applicability and has the potential to enhance antitumor responses when utilized in conjunction with a diverse array of CAR constructs. The gene discussed is KLRK1; the disease is neoplasm.